Thank you for sharing!

Your article was successfully shared with the contacts you provided.

When the government of India revoked U.S. drug maker Pfizer Inc.’s local patent for its cancer drug Sutent last week, it marked yet another loss for Big Pharma in an escalating patent war between multinational pharmaceutical companies and the governments of developing nations. The decision by the country’s patent authority—the Patent Controller of India—to reverse a 2007 decision granting patent protection on the drug, which is used to treat kidney cancer, comes on the heels of other rulings in which some of the world’s largest drug makers have seen their patents on expensive (and potentially lucrative) cancer medicines threatened. For example:

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.